administrative history

CBER Review Committee

Product/Committee Chair: Terrye Zaremba, Ph.D.

Product Review Staff Terrye Zaremba, Ph.D., Product Reviewer

Leon Epps, Ph.D., Radiation Chemistry

Reviewer

Keith Webber, Ph.D. Dep. Div.

Director

Kathryn Stein, Ph.D., Director, DMA

Clinical Review Staff: Steven Litwin, M.D., Medical Reviewer

George Mills, MD, Medical Reviewer,

Branch Chief

Harvey Luksenburg, M.D., Medical

Reviewer

Kaushik Shastri, M.D., Medical Reviewer

Susan Jerian, M.D., Team Leader

Patricia Keegan, M.D., Dep. Div. Director

DCTDA

Biostatistical Review Staff: Satish C. Misra, Ph.D.

Ghanshyam Gupta, Ph.D., Branch Chief

Peter A. Lachenbruch, Ph.D., Div. Director

Clinical Toxicology & Pharmacology: David Green, Ph.D., Branch Chief,

Regulatory Project Manager: Mike Noska

Karen Jones

Compliance/BIMO: Mary Andrich, M.D.

Sponsor: Corixa Corporation

Product: Bexxar (Proprietary name); Tositumomab (murine monoclonal antibody directed against the CD20 antigen) and Iodine I-131-labeled Tositumomab (USAN names)

Proposed indication in Original BLA September 14, 2000

"Iodine I 131 tositumomab is indicated for the treatment of patients with relapsed or refractory low-grade or transformed low-grade, CD20-positive, B-cell non-Hodgkin’s lymphoma."

Revised indication submitted ------------

Corixa submitted a request for standard approval of Bexxar based on demonstration of efficacy in patients with Rituximab refractory follicular non-Hodgkin’s lymphoma. In addition, Corixa requested accelerated approval based on the existence of long-term durable responders (time-to-progression [TTP] of at least one year) in patients with relapsed or refractory, follicular or transformed non-Hodgkin’s lymphoma and who were culled from multiple clinical studies.

The revised proposed indication being sought is

"BEXXARÒ is indicated for the treatment of patients with relapsed or refractory low-grade, follicular or transformed low-grade B-cell non-Hodgkin’s lymphoma (NHL) including patients with Rituximab refractory follicular non-Hodgkin’s lymphoma. Determination of the effectiveness of the BEXXAR therapeutic regimen in relapsed or refractory patient population is based on the existence of long-term durable responders (time-to-progression [TTP] of at least one year) in multiple clinical studies."

Regulatory history

The Investigational New Drug Application (IND) for Bexxar was received on October 13, 1989.

Milestones prior to submission of BLA

[

 

 

 

 

 

 

 

 

 

 

 

]

06/29/99 BLA Application (STN 103906/0) Submitted

08/27/99 FDA Refusal-to-file (RTF) Letter Issued

Milestones for BLA STN 125011/0

09/14/00 BLA Application (STN 125011/0) Submitted

[

 

 

]

03/16/01 FDA Complete Review (CR) Letter Issued

[

 

 

]

03/12/02 FDA Complete Review Letter Issued

[

]

05/31/02 Request for Dispute Resolution Submitted

06/26/02 FDA Other Letter re: Dispute Resolution Issued

[

 

 

 

 

 

 

]